Bookmark
Print
Recommend
  • Home
  • About PBS/IC
    • Overview
    • Nomenclature
    • Causes
    • Diagnosis
      • Overview
      • Diagnostic flow
      • NIDDK
      • Differential diagnosis
    • Management
    • Patients
      • Patient quotes
      • Case studies
    • COB Foundation Survey
      • Overview
      • Diagnosis
      • Symptoms
      • Quality of life
      • Economic impact
    • Clinical Phenotyping
      • Background to UPOINT
      • What is UPOINT
      • UPOINT research
    • References
  • Product information
    • Overview
    • Efficacy
      • Study 1
      • Study 2
    • Tolerability
    • Volume
    • Optimum dose of chondroitin sulfate
    • Budget impact
    • Mode of Action
    • Rationale for using chondroitin sulfate for PBS/IC
      • Importance of bladder GAG layer
      • Importance of chondroitin sulfate in bladder wall GAG layer
      • Dr Hurst Presentation video
    • How to administer Uracyst
    • Recommended treatment plan
    • References
  • Resources
  • KOL webcast
  • Prescribing information & adverse incident reporting
  • Request a call back

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Dr Nickel
Interview

Click here
to watch the
interview in full

MOA
Animation

Watch the
mode of action video now

           Email
           updates

Sign up today and receive regular website updates

Where am I: Product information > Volume

Instillation volume

Each vial of Uracyst contains 400mg of chondroitin sulfate in a 20ml solution.

Volume of Uracyst vs. Cystistat and Gepan

 

Active ingredient

Amount of active ingredient/vial

Volume of solution/vial

Uracyst 2%

Chondroitin sulfate

400mg

20ml

Gepan 0.2%

Chondroitin sulfate

80mg

40ml

Cystistat

Sodium hyaluronate

40mg

50ml

  • Uracyst contains the smallest volume of solution to be instilled in the bladder per treatment.
  • A difference of 20 or 30ml may be substantial for some patients with PBS/IC, particularly in terms of holding the solution in the bladder for the recommended period of time
  • Uracyst may be more suitable than Gepan for patients with shrunken bladders, due to the lower instillation volume per treatment

 

Home | About PBS/IC | Product information | Resources | KOL webcast | Prescribing information & adverse incident reporting | Request a call back | Contact us | Privacy | Sitemap | Copyright